Trial Profile

A phase I/II study of THV02 in patients with adult T-cell Leukemia/Lymphoma.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs THV 02 (Primary)
Indications Adult T-cell leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors THERAVECTYS

Most Recent Events

12 Feb 2015 New trial record
04 Feb 2015 According to Theravectys media release, European Medicines Agency (EMA) has granted Orphan Drug Designation to THV02 for the treatment of adult T-cell leukemia/lymphoma.
04 Feb 2015 According to Theravectys media release, recruitment is planned to begin at the end of Q3 2015 in Europe and further proceed to the U.S and Japan in 2016.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com